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Background: Major depressive disorder (MDD) is a common, debilitating disorder with substantial so-
cioeconomic burden. Many patients with MDD experience symptoms that impair functioning and pro-
ductivity, often negatively affecting work or educational pursuits. This Phase 3b open-label study eval-
uated adjunctive brexpiprazole in young adults with MDD, who were in work or study.
Methods: Young patients (18–35 years) with MDD (inadequate responders to 1–3 antidepressant treat-
ments [ADT] for their current episode) received brexpiprazole 1–3 mg/day (target dose, 2 mg/day) ad-
junctive to the same stable dose of ADT for 12 weeks.
Results: Depressive symptoms improved during treatment with adjunctive brexpiprazole (primary
endpoint, least squares [LS] mean change from baseline in Montgomery-Åsberg Depression Rating Scale
[MADRS] total score, 18.1 [po0.0001]). Reductions from baseline in Sheehan Disability Scale Score
(SDS; LS mean change 11.2 [po0.0001]) and Work Limitations Questionnaire (WLQ; po0.0001) in-
dicated improvements in the effects of patients' symptoms on functioning (work/school, social life, and
home responsibilities). Changes from baseline in additional measures supported improvements in pa-
tient functioning and depression symptoms. The most common adverse events were headache (21.3%),
weight increase (17.0%), and somnolence (17.0%); reported rates of akathisia were low (6.4%). Clinically
relevant increases in weight (Z7%) occurred in 10.5% of patients.
Limitations: Open-label design; absence of comparator.
Conclusions: Brexpiprazole may represent an effective therapy for adjunctive treatment strategy of
young adults with MDD who are working or studying. The observed improvements in work/school
functioning in patients with MDD, whose depression was treated with ADTþbrexpiprazole, suggests
potential to reduce socioeconomic burden.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Major depressive disorder (MDD) is a recurrent, chronic, and
seriously impairing disorder that is associated with substantial
symptom severity (Andrade et al., 2003; Kessler et al., 2003; Bel-
maker and Agam, 2008). Patients with MDD experience a wide
range of physical, cognitive, and emotional symptoms, which can
impair multiple domains of patient functioning (Kessler, 2012),B.V. This is an open access article u
l Center Durham, Universityincluding their ability to function socially, maintain family rela-
tions, and perform productively in a work environment (Belmaker
and Agam, 2008). In addition, depression is associated with a high
economic burden from direct and indirect economic costs; in 2000
its economic burden was estimated to be $83 billion (Halpern
et al., 2013; Greenberg et al., 2015). A recent global return on in-
vestment analysis has suggested that scaling-up treatment of de-
pression in order to achieve even a modest improvement in ability
to work and productivity may lead to large economic gains
(Chisholm et al., 2016).
Multiple dimensions of job performance can be impaired by
depression and thus contribute to its economic burden. Symptoms
of depression are related to impaired performance and functioningnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Additionally, psychosocial work stressors can add to the burden of
depression (Lerner et al., 2010). As such, the personal earnings
and household income of people with depressive symptoms are
substantially lower than those without depression, and many pa-
tients with MDD experience unemployment and loss of income,
which contributes to socioeconomic impact (Whooley et al., 2002;
Birnbaum et al., 2010; Kessler, 2012; Greenberg et al., 2015).
Moreover, the STAR*D study found that patients in lower socio-
economic groups and patients of a younger age were more likely
to discontinue initial treatment (Warden et al., 2009).
The majority of patients who experience mental illness have a
desire to work (McQuilken et al., 2003), and young adults with
MDD should be supported to pursue work or study (Krueger et al.,
2015). However, studies have shown that young people with de-
pression are at signiﬁcant risk of educational underachievement
(Fergusson and Woodward, 2002) and adolescent males with de-
pression are signiﬁcantly less likely to graduate from schools or
colleges beyond high school (Jonsson et al., 2010). Treatment of
young patients with MDD should improve social functioning and
performance in a work or educational setting, as well as alleviate
depressive symptoms and promote recovery from the depressive
episode. Although multiple treatment options currently exist for
MDD, most patients with MDD do not achieve an adequate re-
sponse or remission (Han et al., 2013). Approximately 50% of pa-
tients do not respond effectively to antidepressant treatment
(ADT) (Papakostas, 2009a; Connolly and Thase, 2011), and rates of
relapse have been shown to be more frequent in patients who
require multiple lines of treatment (Rush et al., 2006). A recent
review has also reported inconsistent results regarding the bene-
ﬁts of selective serotonin re-uptake inhibitors (SSRIs) and ser-
otonin-norepinephrine re-uptake inhibitors (SNRIs) on work ab-
sences (Nieuwenhuijsen et al., 2014). As such, there is a need to
develop more effective treatments to improve symptoms of MDD
and contribute to a better work/school function.
The serotonin-dopamine activity modulator, brexpiprazole, has
demonstrated efﬁcacy as an adjunctive treatment in patients with
MDD with an inadequate response to treatment (Thase et al.,
2015a, 2015b). Brexpiprazole has a unique pharmacological proﬁle,
acting as a partial agonist at serotonin 5-HT1A and dopamine D2
receptors, and an antagonist at serotonin 5-HT2A and noradrena-
line alpha1B/2C receptors, with similar subnanomolar binding afﬁ-
nity (Maeda et al., 2014). This unique pharmacological proﬁle also
suggests a low potential for activating or sedating adverse events
(Laoutidis and Luckhaus, 2014; Maeda et al., 2014) that may ben-
eﬁt patients who are working or in school.
The objective of this study was to evaluate brexpiprazole as an
adjunctive treatment in young adults (aged 18–35 years) with MDD
who showed inadequate response to their current SSRI or SNRI
treatment and who were in a work or school environment. In
keeping with the objectives, the primary outcome measure was the
improvement in depressive symptoms, as measured by the Mon-
tgomery-Åsberg Depression Rating Scale (MADRS), while the focus
of the additional outcome measures was on patient functioning, as
assessed by functional scales. This was the ﬁrst study to evaluate
the effect of adjunctive brexpiprazole on the ability of young adults
with MDD to function in a work or school environment.2. Methods
This was a phase 3b, multicenter, open-label, ﬂexible-dose,
exploratory study, conducted between November 25, 2013 and
October 22, 2014, to evaluate brexpiprazole as an adjunctive
treatment in young adults with MDD who were in a work or
school environment.2.1. Patients
Male and female patients aged 18–35 years with a diagnosis of
a single or recurrent, non-psychotic episode of MDD (as deﬁned by
the Diagnostic and Statistical Manual of Mental Disorders, Fourth
edition, Text Revision [DSM-IV-TR], and conﬁrmed by the Mini
International Neuropsychiatric Interview [M.I.N.I] and a clinical
psychiatric evaluation) of at least 6 weeks duration were recruited
at 15 sites in the U.S. Eligible patients were in a school or work
environment (as deﬁned by working Z20 h per week and/or
taking Z6 credit hours per week in school or college) and had
inadequate response to 1–3 ADTs for their current episode (as
deﬁned by o50% reduction in Antidepressant Treatment Re-
sponse Questionnaire [ATRQ] score). Further inclusion criteria in-
cluded: Hamilton Depression Scale (HAM-D17) (Guy, 1976a; Ha-
milton, 1960) total score Z18 at screening and baseline; Sheehan
Disability Scale (SDS) mean score Z5 at baseline; and receipt of
treatment with a single SSRI or SNRI for Z6 weeks prior to
screening (permitted SSRIs: escitalopram 10–20 mg/day, ﬂuox-
etine 20–40 mg/day, paroxetine CR 25–50 mg/day, and sertraline
50–200 mg/day; permitted SNRIs: duloxetine 40–60 mg/day and
venlafaxine XR 75–225 mg/day).
Patients were excluded from the study if they had received
adjunctive antipsychotic treatment for their current episode (Z3
weeks), had received electroconvulsive therapy or transcranial
magnetic stimulation for their current episode, had a current di-
agnosis of any other psychiatric disorder or serious medical con-
dition, had hallucinations or delusions during the current episode
of MDD, or were at serious risk of suicide.
2.2. Study design
The study consisted of a screening period (r3 weeks) in which
patients continued their current SSRI or SNRI ADT monotherapy
treatment at the same dose, baseline assessments at Week 0, and a
12 week open-label period in which patients received brexpipra-
zole 1–3 mg/day adjunctive to the same stable dose of ADT. The
brexpiprazole dose was titrated from 0.5 mg/day (ﬁrst week) to
1 mg/day (second week). Brexpiprazole 2 mg/day was the target
dose for Weeks 3–12; adjustment to 1 mg/day or 3 mg/day was
permitted after Week 3 for tolerability or efﬁcacy based on in-
vestigator judgement. There was a safety follow-up period of 30
(72) days. The study was reviewed and approved by the gov-
erning institutional review board or independent ethics commit-
tee for each investigational site or country.
2.3. Assessments
2.3.1. Function and efﬁcacy
The primary efﬁcacy endpoint was the change from baseline to
Week 12 in MADRS total score (Montgomery and Åsberg, 1979).
MADRS was assessed at baseline, then weekly for the ﬁrst 4 weeks,
and every other week of the treatment period thereafter.
Functional beneﬁts of adjunctive treatment with brexpiprazole
were assessed through evaluation of changes from baseline in a
range of patient-assessed functional scales. Functional scales were
administered at baseline and Weeks 6 and 12 of the treatment
period.
Functioning was assessed using the SDS score (Sheehan et al.,
1996), a patient-rated instrument, which measured work/school,
social life, and family/home responsibilities. Changes from base-
line in the absolute score and single-item subscores were re-
ported; SDS baseline domain scores of 6 and above are associated
with substantial functional impairment. The impact of depression
on work life was assessed using the Work Limitations Ques-
tionnaire (WLQ) (Lerner et al., 2001), a patient-rated instrument.
Table 1
Demographic and baseline clinical characteristics (FAS).
ADTþbrexpiprazole (n¼47)
Demographic characteristics
Age, years, mean (SD) 26.6 (4.9)
BMI, kg/m2, mean (SD) 28.1 (7.6)
Gender, n (%)
Female 32 (68.1)
Male 15 (31.9)
Race, n (%)
Caucasian 37 (78.7)
Black or African American 8 (17.0)
American Indian or Alaska Native 1 (2.1)
Other 1 (2.1)
Clinical characteristics
Current ADT, n (%)
Escitalopram 13 (27.7)
Sertraline 13 (27.7)
Fluoxetine 7 (14.9)
Paroxetine CR 6 (12.8)
Venlafaxine XR 6 (12.8)
Duloxetine 2 (4.3)
Duration of current episode, months
Mean (SD) 14.1 (26.2)
Median (minimum, maximum) 7.0 (2.3, 166.9)
Number of lifetime episodes
Mean (SD) 2.5 (1.2)
Median (minimum, maximum) 2.0 (1.0, 6.0)
MADRS total score, mean (SD) 28.3 (6.4)
CGI-S score, mean (SD) 4.3 (0.5)
HAM-D17 total score, mean (SD) 22.9 (3.5)
KSQ total score, mean (SD) 51.3 (16.0)
SDS, mean (SD)
Absolute score 19.5 (3.4)
Work/school 6.0 (1.8)
Social life 6.9 (1.6)
Family life 6.6 (1.6)
WLQ, mean (SD)
Time demands subscale score 48.4 (22.7)
Physical demands subscale score 26.1 (23.3)
Mental-interpersonal demands subscale 44.6 (20.9)
Output demands subscale 47.8 (29.5)
SASS total score, mean (SD) 30.0 (6.7)
MGH-CPFQ total score, mean (SD) 26.1 (5.5)
ADT, antidepressant treatment; BMI, body mass index; CGI-S, Clinical Global Im-
pression-Severity; CR, controlled release; FAS, full analysis set; HAM-D17, Hamilton
Depression Scale; KSQ, Kellner Symptom Questionnaire; MADRS, Montgomery-
Åsberg Depression Rating Scale; MGH-CPFQ, Massachusetts General Hospital
Cognitive and Physical Functioning Questionnaire; SASS, Social Adaptation Self-
Evaluation Scale; SD, standard deviation; SDS, Sheehan Disability Scale; XR, ex-
tended release; WLQ, Work Limitations Questionnaire.
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Adaptation Self-Evaluation Scale (SASS) (Bech et al., 2002). Cog-
nitive and executive dysfunction, (including symptoms of fatigue,
motivation, alertness, and physical well-being) were assessed
using the Massachusetts General Hospital Cognitive and Physical
Function Questionnaire (MGH-CPFQ) (Fava et al., 2009). Changes
from baseline in MGH-CPFQ total score were reported.
Other secondary efﬁcacy assessments included changes from
baseline to Week 12 in Clinical Global Impression-Severity (CGI-S)
score (Guy, 1976a), HAM-D17 (Guy, 1976a; Hamilton, 1960), and
Kellner Symptom Questionnaire (KSQ) (Kellner, 1987). Clinical
Global Impression-Improvement (CGI-I) score, MADRS response
rate, MADRS remission rate, and CGI-I response rate were assessed
at Week 12. MADRS response rate was deﬁned as Z50% reduction
in MADRS total score from baseline to Week 12 and MADRS re-
mission was deﬁned as MADRS total score r10 and Z50% re-
duction in MADRS total score from baseline to Week 12. CGI-I
response rate was deﬁned as a CGI-I score of 1 or 2 (very much
improved or much improved, respectively).
2.3.2. Safety and tolerability
Safety and tolerability evaluations in this study included ad-
verse events (AEs), laboratory and metabolic assessments (in-
cluding prolactin), physical examinations, vital signs, and electro-
cardiograms (ECGs). AEs and serious AEs (SAEs) were assessed at
all study visits; clinical laboratory assessments were performed at
screening and Weeks 6 and 12; physical examinations were per-
formed at screening and Week 12; vital signs were assessed at
screening, baseline, and at the same intervals as the primary
outcome measure; body weight was assessed at screening and
Weeks 6 and 12; and ECGs were recorded at screening, and Weeks
6 and 12. Extrapyramidal symptoms (EPS) were assessed at base-
line, and Weeks 6 and 12 using the Simpson Angus Scale (SAS)
(Simpson and Angus, 1970), Abnormal Involuntary Movement
Scale (AIMS) (Guy, 1976b), and Barnes Akathisia rating Scale
(BARS) (Barnes, 1989). Suicidality was assessed at all study visits
using the Columbia-Suicide Severity Rating Scale (C-SSRS) (Posner
et al., 2011).
2.3.3. Statistical analysis
The full analysis set (FAS) comprised all patients who had re-
ceived at least 1 dose of study drug, and who had a baseline as-
sessment and at least 1 post-baseline efﬁcacy assessment. The
safety analysis set (SAF) comprised all patients who had received
at least 1 dose of study drug.
Changes from baseline to Week 12 in MADRS, CGI-S, HAM-D17,
KSQ, SDS, WLQ, SASS, and MGH-CPFQ were analyzed using a
mixed model repeated measures (MMRM) analysis, using ob-
served cases with the visit and baseline score as ﬁxed effects and
baseline score-by-visit interaction, on the FAS. A signiﬁcance
criterion of 0.05 was used when testing the null hypothesis of no
change from baseline. MADRS response, MADRS remission, and
CGI-I response rates at Week 12 were based on last observation
carried forward (LOCF) data. Safety data were reported descrip-
tively. No formal sample size calculation or multiplicity adjust-
ments were performed for this trial.3. Results
3.1. Patient disposition
In total, 66 patients were screened and of these, 48 were en-
rolled in the study. A total of 47/48 patients (97.9%) received at
least 1 dose of study drug and entered the FAS and SAF. Of these,
29 patients (61.7%) completed the study and 18 patients (38.3%)were discontinued from study drug. The reasons for discontinua-
tion were withdrawal of consent (9/47, 19.1%), patient lost to fol-
low-up (3/47, 6.4%), occurrence of AEs (3/47, 6.4%), and patient met
withdrawal criteria (3/47, 6.4%). Of the 47 patients who were ex-
posed to at least 1 dose of brexpiprazole, 20 (42.6%) were exposed
to brexpiprazole for Z12 weeks. A total of 29 patients (61.7%)
were exposed to brexpiprazole for Z11 weeks, with a mean daily
dose of 1.93 mg (range 0.8–3.0 mg). The mean dose of brexpipra-
zole at the study endpoint was 1.85 mg (median [minimum,
maximum], 2.00 mg [0.5, 3.0]).
Demographics and baseline characteristics are shown in Ta-
ble 1. The mean MADRS score at baseline was 28.3, indicating that
the patients had moderate to severe depressive symptoms. A total
of 37 patients (78.7%) had recurrent episodes of depression; 10
patients (21.3%) were experiencing their ﬁrst episode of depres-
sion when they entered the study. During the current episode, 41
patients (87.2%) reported an inadequate response to one ADT,
while ﬁve (10.6%) and one (2.1%) had an inadequate response to
two and three ADTs, respectively. Of the 47 patients, 39 (83.0%)
were being treated with an SSRI (escitalopram, sertraline,
Fig. 1. Improvements in depressive symptoms (FAS population). LS mean (SE)
change from baseline to Week 12: 18.1 (1.4), po0.0001 vs. baseline. ***,
po0.0001 vs. baseline, MMRM. FAS, full analysis set; LS, least squares; MADRS,
Montgomery-Åsberg Depression Rating Scale; SE, standard error.
Fig. 2. Mean changes at Week 12 in functional scales (FAS population). A. SDS
absolute score and work/school, social life, and family life/home responsibilities
subscores are shown. B. WLQ time demands, personal demands, mental/inter-
personal demands, and output demands subscales are shown. ***, po0.0001 vs.
baseline, MMRM. FAS, full analysis set; LS, least squares; SDS, Sheehan Disability
Scale; SE, standard error; WLQ, Work Limitations Questionnaire.
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with an SNRI (venlafaxine XR or duloxetine) (Table 1).
3.2. Functional and efﬁcacy results
The primary endpoint for this study, change from baseline at
Week 12 in MADRS total score, was met. The least squares (LS)
mean (standard error [SE]) change in MADRS total score at Week
12 was 18.1 (1.4, po0.0001 vs. baseline [Fig. 1]). Reductions in
depressive symptoms from baseline were observed across all time
points of the treatment period (po0.0001 vs. baseline [Fig. 1]).
3.3. Functional assessments
All self-reported measures of function showed signiﬁcant im-
provement after treatment with brexpiprazole. Improvements in
patients' symptoms relating to work/school, social life, and family/
home responsibilities were observed at Week 12, as evidenced by
reductions in SDS absolute score (po0.0001) and consistent re-
ductions across the SDS subscale scores for work/school
(po0.0001), social life (po0.0001), and family life (po0.0001)
[Fig. 2(A)]. Improvements were also observed at Week 6 for the
SDS absolute score; LS mean (SE) change from baseline for the
total SDS score at Week 6 was 9.1 (1.1), po0.0001 vs. baseline.
The LS mean (SE) changes from baseline at Week 6 for the work/
school, social life and family life/home responsibilities subscores
were 2.9 (0.4), 3.2 (0.4), and 3.1 (0.4) [all po0.0001 vs.
baseline], respectively.
Improvements from baseline in school and work productivity
were seen at Week 12, based on WLQ score; improvements were
also seen in all of the 4 subscale scores (time demands, physical
demands, mental-interpersonal demands, and output demands;
po0.0001 vs. baseline) [Fig. 2(B)]. LS mean [SE] changes in the
WLQ subscales at Week 6 also conﬁrmed improvements from
baseline (time demands, 17.0[4.1] p¼0.0002; physical demands,
10.5 [3.2] p¼0.0019; mental-interpersonal demands, 15.6
[3.7] p¼0.0001; output demands, 18.2 [4.1] po0.0001).
A summary of secondary efﬁcacy results are presented in Ta-
ble 2. Improvements in social function, motivation, and behavior
were demonstrated by increased SASS total score at Week 12
(po0.0001; Week 6 LS mean [SE] change from baseline in SASS
was 7.0 [1.2], po0.0001). Mean changes from baseline at Week 12
in MGH-CPFQ total score indicated that there were also improve-
ments in symptoms of fatigue, motivation, alertness, and physicalwell-being (po0.0001; Week 6 LS mean [SE] change from base-
line in MGH-CPFQ was 6.6 [1.0], po0.0001).
3.4. Depression assessments
Improvements in depressive symptoms, as assessed by the sec-
ondary outcome measures CGI-S, HAM-D17 and KSQ total score at
Week 12, all supported the observed improvements in MADRS total
score (all po0.0001 vs. baseline) [Table 2]. Improvements were
seen from ﬁrst assessment for CGI-S score (Week 1, p¼0.0011) and
HAM-D17 (Week 6, po0.0001) and KSQ (Week 6, po0.0001).
Mean changes in KSQ total score indicated improvements in de-
pression, anxiety, anger-hostility, and somatic symptoms.
At Week 12, more than 50% of patients were responders, with
53.2% of patients demonstrating a MADRS response and 63.8%
demonstrating a CGI-I response. The proportion of patients
achieving MADRS remission (MADRS score r10) was 42.6%.
3.5. Safety and tolerability
A summary of treatment emergent AEs (TEAEs) is presented in
Table 3. A total of 39 patients (83.0%) reported Z1 TEAE. The most
frequently reported AEs were headache, weight increase, and
somnolence. No patients died and none reported an SAE during
Table 2
Summary of efﬁcacy results at Week 12.
Variable ADTþbrexpiprazole (n¼47)
Functional assessments
SASS total score
n 28
LS mean (SE) changea,b 9.7 (1.6)
95% CI 6.4, 12.9
p-value o0.0001
MGH-CPFQ total score
n 28
LS mean (SE) changea,b 8.1 (1.3)
95% CI 10.8, 5.4
p-value o0.0001
Depression assessments
CGI-S
n 28
LS mean (SE) changea,b 2.0 (0.2)
95% CI 2.4, 1.7
p-value o0.0001
HAM-D17 total score
n 28
LS mean (SE) changea,b 14.9 (1.1)
95% CI 17.1, 12.6
p-value o0.0001
KSQ total score
n 28
LS mean (SE) changea,b 30.5 (3.6)
95% CI 37.8, 23.3
p-value o0.0001
CGI-I score
Mean (SD) value at Week 12 (LOCF) 2.2 (1.3)
CGI-I response rate
Responders at Week 12, n (%)c [LOCF] 30 (63.8)
95% CI 48.5, 77.3
MADRS response rate
Responders at Week 12, n (%)c [LOCF] 25 (53.2)
95% CI 38.1, 67.9
MADRS remission rate
Remitters at Week 12, n (%)c [LOCF] 20 (42.6)
95% CI 28.3, 57.8
ADT, antidepressant treatment; CGI-I, Clinical Global Impression-Improvement; CI,
conﬁdence interval; CGI-S, Clinical Global Impression-Severity of Illness; FAS, full
analysis set; HAM-D17, Hamilton Depression rating scale; KSQ, Kellner Symptom
Questionnaire; LS, least squares; LOCF, last observation carried forward; MADRS,
Montgomery-Åsberg Depression Rating Scale; MGH-CPFQ, Massachusetts General
Hospital Clinical and Physical Function Questionnaire; MMRM, mixed model re-
peated measures; SASS, Social Adaptation Self Evaluation Scale; SD, standard de-
viation; SE, standard error.
a LS mean change from baseline to Week 12.
b Statistical analyses were performed on the FAS using MMRM.
c Percentages based on FAS (n¼47).
Table 3
Summary of adverse events.
n (%) ADTþbrexpiprazole (n¼47)
Patients with TEAEs 39 (83.0)
Patients with TEAE leading to withdrawal 3 (6.4)
TEAEs reported by Z5% patients
Headache 10 (21.3)
Weight increased 8 (17.0)
Somnolence 8 (17.0)
Anxiety 6 (12.8)
Nausea 5 (10.6)
Insomnia 5 (10.6)
Diarrhea 4 (8.5)
Dizziness 4 (8.5)
Sedation 4 (8.5)
Abdominal discomfort 3 (6.4)
Increased appetite 3 (6.4)
Akathisia 3 (6.4)
Depression 3 (6.4)
Libido decreased 3 (6.4)
EPS-related AEs
Patients experiencing EPS events, n (%) 4 (8.5)
Dystonic events 0 (0.0)
Parkinsonian events 0 (0.0)
Akathisia 3 (6.4)
Dyskinetic events 0 (0.0)
Myoclonus 1 (2.1)
ADT, antidepressant treatment; AE, adverse event; EPS, extrapyramidal symptom;
TEAE, treatment-emergent adverse event.
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depression, insomnia, and somnolence; the AE of insomnia was
assessed to be related to study drug and the AE of somnolence was
considered to be possibly related to study drug. The majority of
TEAEs were mild or moderate in severity. Three TEAEs of head-
ache, insomnia, and decreased libido were assessed as severe by
the investigator; each occurred in 1 patient (2.1%). A total of
4 patients (8.5%) reported EPS-related TEAEs during the study
(akathisia, 3 [6.4%]; myoclonus, 1 [2.1%]). The small changes from
baseline observed for SAS, AIMS, and BARS at Week 12 were not
considered to be clinically relevant by the investigators, and no
patients were assessed as having marked or severe akathisia
during the study. During the study there were no patients with
suicidal behavior, as assessed by the C-SSRS.
3.6. Laboratory and metabolic assessments
No clinically relevant changes from baseline were reported for
liver-related, creatine phosphokinase, renal parameter, orhematology laboratory tests. No notable trends were observed in
mean changes from baseline for urinalysis. Mean changes from
baseline and FDA-deﬁned treatment emergent changes in meta-
bolic parameters (from fasting blood samples) and prolactin are
shown in Table 4.
3.7. Body weight and vital signs
The mean (standard deviation) change from baseline to last visit
in body weight was 1.36 (2.92) kg. A total of 4/38 patients (10.5%)
reported a weight increase Z7% from baseline; 1/38 patients (2.6%)
reported a weight decrease Z7% from baseline.
Mean changes from baseline in vital signs were minimal. Po-
tentially clinically relevant changes in vital signs were observed in
a total of 3 patients, including increased standing heart rate, in-
creased standing diastolic blood pressure, and orthostatic hypo-
tension. A total of 3 patients experienced potentially clinically
relevant abnormalities in ECG evaluations; 2 patients (4.3%) ex-
perienced a sinus bradycardiac abnormality (r50 beats per
minute) and 1 patient (2.1%) experienced symmetrical T-wave
inversion.4. Discussion
The aim of this exploratory, open-label study was to evaluate
ﬂexibly-dosed adjunctive brexpiprazole treatment in active young
adults with MDD. Patients were aged 18–35 years and were ex-
periencing inadequate SSRI/SNRI response in a school or work
environment of at least 20 h/week. In patients receiving brexpi-
prazole at a range of 1–3 mg as an adjunctive treatment to ADT,
symptoms of depression were improved, as well as functioning in
young patients working or at school.
Improvements in depressive symptoms were observed with
adjunctive brexpiprazole treatment, as evidenced by improve-
ments in MADRS total score, HAM-D17 total score, CGI-S, and CGI-I,
consistent with ﬁndings from previous phase 3 studies (Thase
et al., 2015a, 2015b) and summarized in a comprehensive review
Table 4
Mean change from baseline to Week 12 in metabolic parameters.
Parameters ADTþbrexpiprazole (n¼47)
Cholesterol, mg/dL
n 24
Change from baseline to Week 12, mean (SD) 9.0 (18.6)
Incidence of treatment emergent changea,b
Normal to high, n (%) 0/24 (0.0)
HDL cholesterol, mg/dL
n 24
Change from baseline to Week 12, mean (SD) 4.0 (6.8)
Incidence of treatment emergent changea,c
Normal to low, n (%) 3/30 (10.0)
LDL cholesterol, mg/dL
n 25
Change from baseline to Week 12, mean (SD) 11.0 (17.8)
Incidence of treatment emergent changea,d
Borderline to high, n (%) 0/21 (0.0)
Normal/borderline to high, n (%) 0/36 (0.0)
Normal to borderline high, n (%) 1/15 (6.7)
Triglycerides, mg/dL
n 24
Change from baseline to Week 12, mean (SD) 22.8 (77.2)
Incidence of treatment emergent changea,e
Normal to high, n (%) 3/29 (10.3)
Normal/borderline to high, n (%) 5/32 (15.6)
Normal to borderline/high/very high, n (%) 5/29 (17.2)
Glucose, mg/dL
n 24
Change from baseline to Week 12, mean (SD) 0.0 (9.8)
Incidence of treatment emergent changea,f
Normal to high, n (%) 0/34 (0.0)
Normal/impaired to high, n (%) 1/36 (2.8)
ADT, antidepressant treatment; HDL, high density lipoprotein; LDL, low density
lipoprotein; SD, standard deviation.
a Number of patients with metabolic parameters measurements within the
normal range at baseline and outside the normal range at any time during the
study.
b Fasting cholesterol measurements: normal, o200 mg/dL; high, 4240 mg/
dL.
c Fasting HDL cholesterol measurements: normal, Z40 mg/dL; low, o40 mg/
dL.
d Fasting LDL cholesterol measurements: borderline, 100–o160 mg/dL;
normal, o100 mg/dL; normal/borderline, o160 mg/dL; borderline/high,
Z100 mg/dL.
e Fasting triglycerides measurements: normal, o150 mg/dL; borderline/high/
very high, Z150 mg/dL; normal/borderline, o200 mg/dL; high, 200–o500 mg/
dL.
f Fasting glucose measurements: normal, o100 mg/dL; normal/impaired,
o126 mg/dL; high, Z126 mg/dL.
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ments in MADRS total score were seen from Week 1, indicating
that there was a rapid onset of improvements in depressive
symptoms in patients who were treated with adjunctive brexpi-
prazole. Additionally, consistent increases in the proportions of
MADRS responders and remitters were observed throughout the
study period from Week 1. The increased proportions of re-
sponders over time suggests that patients with inadequate re-
sponse to their ADT may experience meaningful clinical beneﬁts
with adjunctive brexpiprazole treatment. While improvement in
depression (changes in MADRS) was clearly important, and the
primary outcome measure of the study, the observed changes in
patients' function in a work/school setting were another main
research interest for the study. Improvements in work productivity
and occupational functioning have been observed in conjunction
with improvements in depressive symptoms (Trivedi et al., 2013),
and it has been demonstrated that early reductions in depressive
symptoms predict subsequent improvements in work outcomes
(Hees et al., 2013). The rapid improvement in MADRS total score
observed here suggests that treatment with adjunctive brexpi-
prazole could lead to beneﬁts in functioning and workproductivity for patients with MDD.
Restoration of psychosocial function is a critical therapeutic
goal for patients receiving treatment for MDD (Papakostas, 2009b).
In this study, marked improvements in patient-rated scales of
functioning were observed. At Week 12, consistent improvements
were seen in patient functioning, based on changes from baseline
in SDS, WLQ, SASS, and MGH-CPFQ. Improvements in function
were also observed at Week 6. Although not directly comparable,
the improvements in SDS scores observed here are large, com-
pared with improvements in SDS scores observed in other studies
of adjunctive quetiapine and olanzapine treatment (Sheehan and
Sheehan, 2008; Sheehan et al., 2012; Brunner et al., 2014). The
improvements observed here in the work/school subscales of the
SDS and WLQ suggest that young adults with inadequate response
to their current ADT may beneﬁt from adjunctive brexpiprazole.
These results suggest that brexpiprazole may potentially con-
tribute to greater success in patients’ academic and employment
pursuits, which is not only desirable from a patient perspective,
but also desirable from a public health and economic perspective.
Additionally, the observed improvements in time management
and mental/interpersonal scales could potentially contribute to
recovery from depression and improved quality of life (Hees et al.,
2013; Ishak et al., 2013).
The implications of the effects of adjunctive brexpiprazole
treatment on work and school functioning of young patients with
MDD are important to consider. In the general population, adult
mortality is increased secondary to failure to complete high school
or college (Krueger et al., 2015). Importantly, an association exists
between unemployment and depression, with several studies
demonstrating that employment status and duration of absence
due to sickness are risk factors for suicide (Classen and Dunn,
2012; Yur'yev et al., 2012; Pompili et al., 2014; Wang et al., 2015).
Currently, the healthcare costs and productivity losses associated
with depression are high (Greenberg et al., 2015). In the USA, U-3
(unemployed, but has actively looked for work in the previous
4 weeks) and U-6 (marginally/loosely attached and discouraged
workers; those wanting to and able to work, but have not looked
for work recently; part-time workers wanting to work full-time
but cannot due to economic reasons) unemployment rates were
5.5–5.7% and 10.9–11.3% for January to March 2015, respectively
(Bureau of Labor Statistics, 2015a). Of these, the unemployment
rates for people aged 18–35 years were 4.4–18.2%, with the highest
rate of unemployment occurring in the 18–19 years age group
(Bureau of Labor Statistics, 2015b). Young patients with MDD
should be supported in their work or educational pursuits, and
addressing the mental health needs of young people is crucial if
they are to fulﬁll their potential and contribute to their commu-
nities and society (Patel et al., 2007). Not providing adequate
support to the younger population is associated with socio-
economic impacts, such as the risk that they may become un-
employable. Such long-term unemployment may mean that
younger patients no longer count in social statistics that measure
unemployment, as they are no longer seeking work, and conse-
quently the social scale of the problem may be underestimated.
It is important to consider that the ability to perform at work or
school is not impaired by the medication(s) prescribed to treat
MDD. With respect to impaired functioning, fatigue and sedation
are both elements of depression (Belmaker and Agam, 2008) and
side effects of antidepressant drugs (Khawam et al., 2006). A fa-
vorable tolerability and safety proﬁle was observed with ad-
junctive brexpiprazole treatment, with low occurrences of side
effects that are deleterious for patients' functioning, such as se-
dation and somnolence, as well as activating side effects such as
akathisia and restlessness. AEs were generally of low severity, and
a low percentage of patients discontinued due to AEs despite that
the present study was 12 weeks compared with 6 weeks for the
R.H. Weisler et al. / Journal of Affective Disorders 204 (2016) 40–4746brexpiprazole registration study program. Over the 12 weeks,
moderate weight gain was observed with adjunctive brexpiprazole
treatment, therefore it is important to monitor weight changes
when using brexpiprazole and consider the overall risk/beneﬁt for
each individual patient. Long-term open-label studies of ad-
junctive brexpiprazole have suggested that weight gain may pla-
teau between Weeks 26 and 52, providing additional risk/beneﬁt
data (Nelson et al., 2015). As the side effect proﬁle of some ad-
junctive atypical antipsychotics can limit their use in clinical
practice (Wright et al., 2013), the tolerability proﬁle and low se-
verity of AEs associated with adjunctive brexpiprazole treatment
could be of beneﬁt for patients with MDD for maintaining work
and educational pursuits.
Limitations of this study included the absence of a comparator
and the open-label study design, which can be viewed as a po-
tential source of bias compared with double-blind study designs.
Also, we cannot differentiate between improved function sec-
ondary to improvements in depressive symptoms, compared with
potential direct effects of brexpiprazole on functional outcomes.
All patients recruited to this study had the diagnosis of MDD
conﬁrmed using a structured diagnostic interview (the M.I.N.I.),
which is known to be very sensitive in detecting bipolar disorder.
However, misdiagnosis has been reported in patients with mood
disorders (Altamura et al., 2015) and may have been a contributing
factor in the inadequate response to ADT for some patients. Pa-
tients had been treated with a range of different ADTs during their
current episode in accordance with usual clinical practice. Ad-
ditionally, longer-term studies to assess the sustained socio-
economic beneﬁts of brexpiprazole would be helpful.
To conclude, the ﬁndings reported here suggest that improve-
ments in multiple dimensions of functioning are associated with
the treatment of depression using adjunctive brexpiprazole. Ad-
junctive treatment with brexpiprazole may represent an effective
strategy for treatment of young adults with MDD who have an
inadequate response to their ADT and who are working or at
school. Improved functioning of patients with MDD may enable
improved performance in a work or school environment, poten-
tially allowing patients to better succeed in their work or educa-
tional pursuits and maintain an income, thereby reducing socio-
economic burden.Role of the funding source
Funding for this study was provided by Otsuka Pharmaceutical
Development & Commercialization, Inc. (Princeton, USA) and H.
Lundbeck A/S (Valby, Denmark). The sponsors were responsible for
the study design, and the collection, and analysis of the data. All
authors were responsible for the interpretation of the data and for
the writing of the manuscript, and had responsibility for the ap-
proval of the submitted article for publication.Acknowledgments
Ruth Steer, PhD (QXV Communications [an Ashﬁeld business,
part of UDG healthcare plc], Macclesﬁeld, UK) provided writing
support which was funded by Otsuka Pharmaceutical Co. Ltd.
(Tokyo, Japan) and H. Lundbeck A/S (Valby, Denmark).References
Adler, D.A., McLaughlin, T.J., Rogers, W.H., Chang, H., Lapitsky, L., Lerner, D., 2006.
Job performance deﬁcits due to depression. Am. J. Psychiatry 163, 1569–1576.
Altamura, A.C., Buoli, M., Caldiroli, A., Caron, L., Cumerlato Melter, C., Dobrea, C.,
Cigliobianco, M., Zanelli Quarantini, F., 2015. Misdiagnosis, duration of un-
treated illness (DUI) and outcome in bipolar patients with psychotic symptoms:a naturalistic study. J. Affect. Disord. 182, 70–75.
Andrade, L., Caraveo-Anduaga, J.J., Berglund, P., Bijl, R.V., de, G.R., Vollebergh, W.,
Dragomirecka, E., Kohn, R., Keller, M., Kessler, R.C., Kawakami, N., Kilic, C.,
Offord, D., Ustun, T.B., Wittchen, H.U., 2003. The epidemiology of major de-
pressive episodes: results from the International Consortium of Psychiatric
Epidemiology (ICPE) Surveys. Int. J. Methods Psychiatr. Res. 12, 3–21.
Barnes, T.R., 1989. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154,
672–676.
Bech, P., Lunde, M., Unden, M., 2002. Social Adaptation Self-evaluation Scale (SASS):
psychometric analysis as outcome measure in the treatment of patients with
major depression in the remission phase. Int. J. Psychiatry Clin. Pract. 6,
141–146.
Belmaker, R.H., Agam, G., 2008. Major depressive disorder. N. Engl. J. Med. 358,
55–68.
Birnbaum, H.G., Kessler, R.C., Kelley, D., Ben-Hamadi, R., Joish, V.N., Greenberg, P.E.,
2010. Employer burden of mild, moderate, and severe major depressive dis-
order: mental health services utilization and costs, and work performance.
Depression Anxiety 27, 78–89.
Brunner, E., Tohen, M., Osuntokun, O., Landry, J., Thase, M.E., 2014. Efﬁcacy and
safety of olanzapine/ﬂuoxetine combination vs ﬂuoxetine monotherapy fol-
lowing successful combination therapy of treatment-resistant major depressive
disorder. Neuropsychopharmacology 39, 2549–2559.
Bureau of Labor Statistics. 2015b. Unemployment Rates by Age, Sex, and Marital
Status, Seasonally Adjusted. Available at: 〈http://www.bls.gov/web/empsit/
cpseea10.htm〉. (accessed 01.05.15.).
Bureau of Labor Statistics. 2015a. The Employment Situation - March 2015. Avail-
able at: 〈http://www.bls.gov/schedule/archives/empsit_nr.htm#current〉. (ac-
cessed 01.05.15.).
Chisholm, D., Sweeny, K., Sheehan, P., Rasmussen, B., Smit, F., Cuijpers, P., Saxena, S.,
2016. Scaling-up treatment of depression and anxiety: a global return on in-
vestment analysis. Lancet Psychiatry 3, 415–424.
Classen, T.J., Dunn, R.A., 2012. The effect of job loss and unemployment duration on
suicide risk in the United States: a new look using mass-layoffs and un-
employment duration. Health Econ. 21, 338–350.
Connolly, K.R., Thase, M.E., 2011. If at ﬁrst you don't succeed: a review of the evi-
dence for antidepressant augmentation, combination and switching strategies.
Drugs 71, 43–64.
Fava, M., Iosifescu, D.V., Pedrelli, P., Baer, L., 2009. Reliability and validity of the
Massachusetts general hospital cognitive and physical functioning ques-
tionnaire. Psychother. Psychosom. 78, 91–97.
Fergusson, D.M., Woodward, L.J., 2002. Mental health, educational, and social role
outcomes of adolescents with depression. Arch. Gen. Psychiatry 59, 225–231.
Greenberg, P.E., Fournier, A.A., Sisitsky, T., Pike, C.T., Kessler, R.C., 2015. The eco-
nomic burden of adults with major depressive disorder in the United States
(2005 and 2010). J. Clin. Psychiatry 76, 155–162.
Guy, W., 1976a. ECDEU assessment manual for psychopharmacology (revised). In:
Hamilton, M. (Ed.), Hamilton Anxiety Scale. National Institute of Mental Health,
Rockville, MD, pp. 193–198.
Guy, W., 1976b. ECDEU Assessment Manual for Psychopharmacology. National In-
stitute of Mental Health, Rockville, MD, pp. 76–338.
Halpern, R., Nadkarni, A., Kalsekar, I., Nguyen, H., Song, R., Baker, R.A., Nelson, J.C.,
2013. Medical costs and hospitalizations among patients with depression
treated with adjunctive atypical antipsychotic therapy: an analysis of health
insurance claims data. Ann. Pharmacother. 47, 933–945.
Hamilton, M., 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry
23, 56–62.
Han, C., Wang, S.M., Kato, M., Lee, S.J., Patkar, A.A., Masand, P.S., Pae, C.U., 2013.
Second-generation antipsychotics in the treatment of major depressive dis-
order: current evidence. Expert. Rev. Neurother. 13, 851–870.
Hees, H.L., Koeter, M.W., Schene, A.H., 2013. Longitudinal relationship between
depressive symptoms and work outcomes in clinically treated patients with
long-term sickness absence related to major depressive disorder. J. Affect.
Disord. 148, 272–277.
Ishak, W.W., Balayan, K., Bresee, C., Greenberg, J.M., Fakhry, H., Christensen, S.,
Rapaport, M.H., 2013. A descriptive analysis of quality of life using patient-re-
ported measures in major depressive disorder in a naturalistic outpatient set-
ting. Qual. Life Res. 22, 585–596.
Jonsson, U., Bohman, H., Hjern, A., von Knorring, L., Olsson, G., von Knorring, A.L.,
2010. Subsequent higher education after adolescent depression: a 15-year fol-
low-up register study. Eur. Psychiatry 25, 396–401.
Kellner, R., 1987. A symptom questionnaire. J. Clin. Psychiatry 48, 268–274.
Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R., Rush, A.J.,
Walters, E.E., Wang, P.S., 2003. The epidemiology of major depressive disorder:
results from the National Comorbidity Survey Replication (NCS-R). J. Am. Med.
Assoc. 289, 3095–3105.
Kessler, R.C., 2012. The costs of depression. Psychiatr. Clin. N. Am. 35, 1–14.
Khawam, E.A., Laurencic, G., Malone Jr., D.A., 2006. Side effects of antidepressants:
an overview. Clevel. Clin. J. Med. 73, 351–361.
Krueger, P.M., Tran, M.K., Hummer, R.A., Chang, V.W., 2015. Mortality attributable to
low levels of education in the United States. PLoS One 10, e0131809.
Laoutidis, Z.G., Luckhaus, C., 2014. 5-HT2A receptor antagonists for the treatment of
neuroleptic-induced akathisia: a systematic review and meta-analysis. Int. J.
Neuropsychopharmacol. 17, 823–832.
Lerner, D., Amick III, B.C., Rogers, W.H., Malspeis, S., Bungay, K., Cynn, D., 2001. The
Work Limitations Questionnaire. Med. Care 39, 72–85.
Lerner, D., Adler, D.A., Rogers, W.H., Chang, H., Lapitsky, L., McLaughlin, T., Reed, J.,
R.H. Weisler et al. / Journal of Affective Disorders 204 (2016) 40–47 472010. Work performance of employees with depression: the impact of work
stressors. Am. J. Health Promot. 24, 205–213.
Maeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita,
H., Ito, N., McQuade, R.D., Mork, A., Pehrson, A.L., Hentzer, M., Nielsen, V.,
Bundgaard, C., Arnt, J., Stensbøl, T.B., Kikuchi, T., 2014. Brexpiprazole I: in vitro
and in vivo characterization of a novel serotonin-dopamine activity modulator.
J. Pharmacol. Exp. Ther. 350, 589–604.
McKeage, K., 2016. Adjunctive brexpiprazole: a review in major depressive disorder.
CNS Drugs 30, 91–99.
McQuilken, M., Zahnisera, J., Novack, J., Starska, R., Olmos, A., Bond, G., 2003. The
work project survey: consumer perspectives on work. J. Vocat. Rehab. 18,
59–68.
Montgomery, S.A., Åsberg, M., 1979. A new depression scale designed to be sen-
sitive to change. Br. J. Psychiatry 134, 382–389.
Nelson J.C., Skuban A., Zhang P., Weiller E., Weiss C. 2015. Long-term safety of ad-
junctive brexpiprazole (OPC-34712) in MDD: Results from two 52-week open-
label studies abstract (no. 57 plus poster). In: Proceedings of the American
Psychiatric Association 168th Annual Meeting, 16–20 May 2015, Toronto,
Canada.
Nieuwenhuijsen, K., Faber, B., Verbeek, J.H., Neumeyer-Gromen, A., Hees, H.L.,
Verhoeven, A.C., van der Feltz-Cornelis, C.M., Bultmann, U., 2014. Interventions
to improve return to work in depressed people. Cochrane Database Syst. Rev.,
12.
Papakostas, G.I., 2009a. Managing partial response or nonresponse: switching,
augmentation, and combination strategies for major depressive disorder. J. Clin.
Psychiatry 70 (Suppl 6), S16–S25.
Papakostas, G.I., 2009b. Major depressive disorder: psychosocial impairment and
key considerations in functional improvement. Am. J. Manag. Care 15,
S316–S321.
Patel, V., Flisher, A.J., Hetrick, S., McGorry, P., 2007. Mental health of young people:
a global public-health challenge. Lancet 369, 1302–1313.
Pompili, M., Innamorati, M., Di, V.C., Baratta, S., Masotti, V., Badaracco, A., Wong, P.,
Lester, D., Yip, P., Girardi, P., Amore, M., 2014. Unemployment as a risk factor for
completed suicide: a psychological autopsy study. Arch. Suicide Res. 18,
181–192.
Posner, K., Brown, G.K., Stanley, B., Brent, D.A., Yershova, K.V., Oquendo, M.A.,
Currier, G.W., Melvin, G.A., Greenhill, L., Shen, S., Mann, J.J., 2011. The Columbia-
Suicide Severity Rating Scale: initial validity and internal consistency ﬁndings
from three multisite studies with adolescents and adults. Am. J. Psychiatry 168,
1266–1277.
Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden,
D., Niederehe, G., Thase, M.E., Lavori, P.W., Lebowitz, B.D., McGrath, P.J., Ro-
senbaum, J.F., Sackeim, H.A., Kupfer, D.J., Luther, J., Fava, M., 2006. Acute andlonger-term outcomes in depressed outpatients requiring one or several
treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905–1917.
Sheehan, D.V., Harnett-Sheehan, K., Raj, B.A., 1996. The measurement of disability.
Int. Clin. Psychopharmacol. 11 (Suppl 3), 89–95.
Sheehan, K.H., Sheehan, D.V., 2008. Assessing treatment effects in clinical trials
with the discan metric of the Sheehan Disability Scale. Int. Clin. Psycho-
pharmacol. 23, 70–83.
Sheehan, D.V., Locklear, J., Svedsater, H., Datto, C., 2012. Long-term functioning and
sleep quality in patients with major depressive disorder treated with extended-
release quetiapine fumarate. Int. Clin. Psychopharmacol. 27, 239–248.
Simpson, G.M., Angus, J.W., 1970. A rating scale for extrapyramidal side effects. Acta
Psychiatr. Scand. Suppl. 212, 11–19.
Thase, M.E., Youakim, J.M., Skuban, A., Hobart, M., Augustine, C., Zhang, P.,
McQuade, R., Carson, W.H., Nyilas, M., Sanchez, R., Eriksson, H., 2015a. Efﬁcacy
and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a
Phase 3, randomized, placebo-controlled study in patients with inadequate
response to antidepressants. J. Clin. Psychiatry 76, 1224–1231.
Thase, M.E., Youakim, J.M., Skuban, A., Hobart, M., Zhang, P., McQuade, R., Nyilas, M.,
Carson, W.H., Sanchez, R., Eriksson, H., 2015b. Adjunctive brexpiprazole 1 and
3 mg for patients with major depressive disorder following inadequate re-
sponse to antidepressants: a Phase 3, randomized, double-blind study. J. Clin.
Psychiatry 76, 1232–1240.
Trivedi, M.H., Morris, D.W., Wisniewski, S.R., Lesser, I., Nierenberg, A.A., Daly, E.,
Kurian, B.T., Gaynes, B.N., Balasubramani, G.K., Rush, A.J., 2013. Increase in work
productivity of depressed individuals with improvement in depressive symp-
tom severity. Am. J. Psychiatry 170, 633–641.
Wang, M., Alexanderson, K., Runeson, B., Mittendorfer-Rutz, E., 2015. Sick-leave
measures, socio-demographic factors and health care as risk indicators for
suicidal behavior in patients with depressive disorders—a nationwide pro-
spective cohort study in Sweden. J. Affect. Disord. 173, 201–210.
Warden, D., Rush, A.J., Wisniewski, S.R., Lesser, I.M., Thase, M.E., Balasubramani, G.
K., Shores-Wilson, K., Nierenberg, A.A., Trivedi, M.H., 2009. Income and attrition
in the treatment of depression: a STAR*D report. Depression Anxiety 26,
622–633.
Whooley, M.A., Kiefe, C.I., Chesney, M.A., Markovitz, J.H., Matthews, K., Hulley, S.B.,
2002. Depressive symptoms, unemployment, and loss of income: the CARDIA
Study. Arch. Intern. Med. 162, 2614–2620.
Wright, B.M., Eiland III, E.H., Lorenz, R., 2013. Augmentation with atypical anti-
psychotics for depression: a review of evidence-based support from the med-
ical literature. Pharmacotherapy 33, 344–359.
Yur’yev, A., Varnik, A., Varnik, P., Sisask, M., Leppik, L., 2012. Employment status
inﬂuences suicide mortality in Europe. Int. J. Soc. Psychiatry 58, 62–68.
